Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix?-Reference-Cited by-同舟云学术

Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix?

Published:2022-04 Issue:4 Volume:22 Page:438-440
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Parker Edward P K,Desai Shalini,Marti Melanie,O'Brien Katherine L,Kaslow David C,Kochhar Sonali,Olayinka Folake,Cravioto Alejandro,Nohynek Hanna,Hombach Joachim,Wilder-Smith Annelies

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference12 articles.

1. An interactive website tracking COVID-19 vaccine development;Shrotri;Lancet Glob Health,2021

2. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada;Skowronski;medRxiv,2021

3. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021;Martínez-Baz;Euro Surveill,2021

4. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against COVID-19 related symptoms in England: test negative case-control study;Andrews;medRxiv,2021

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical coding of long COVID in primary care 2020–2023 in a cohort of 19 million adults: an OpenSAFELY analysis;eClinicalMedicine;2024-06

2. COVID-19 Booster Vaccination Adverse Effects and Willingness to Receive a Yearly Booster Dose among Members of Health Sciences Faculties: A Descriptive Cross-Sectional Study;Journal of Pharmacy and Bioallied Sciences;2024-04

3. Clinical coding of long COVID in primary care 2020-2023 in a cohort of 19 million adults: an OpenSAFELY analysis;2023-12-04

4. A two-arm analysis of the immune response to heterologous boosting of inactivated SARS-CoV-2 vaccines;Scientific Reports;2023-10-31

5. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults;Vaccine;2023-09